New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:40 EDTSHPG, WAG, ABBVShire drops 5% with tax inversions in focus
Shares of Shire (SHPG) are moving lower in pre-market trading after Walgreen (WAG) announced it would stay located in Chicago and Bloomberg last night reported that the Treasury Department is exploring ways to bypass Congress in an attempt to curb corporate inversions. Shire is down 5%, or $13.28, to $232.46 in pre-market trading while AbbVie (ABBV), the company attempting to acquire Shire via a tax inversion, is down 2% to $51.50.
News For SHPG;WAG;ABBV From The Last 14 Days
Check below for free stories on SHPG;WAG;ABBV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
08:12 EDTWAGWalgreen files S-4, prospectus for strategic transaction with Alliance Boots
Subscribe for More Information
September 15, 2014
10:55 EDTSHPG, ABBVRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
08:01 EDTSHPGShire announces FDA acceptance for filing of sNDA for Vyvanse
Subscribe for More Information
September 12, 2014
18:43 EDTWAGCtW Investment calls on Walgreen to provide details on earnings, Reuters says
Subscribe for More Information
07:32 EDTABBVBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
September 11, 2014
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
September 9, 2014
08:00 EDTWAGWalgreen price target lowered to $75 from $85 at Leerink
Subscribe for More Information
07:38 EDTWAGWalgreen pushed to boost buyback as Jana secures seats, Bloomberg says
Walgreen will most likely be pushed to increase a to $3B share buyback program that let down investors in August after Jana Partners reached an agreement on three board seats at the company, according to Bloomberg, citing a person familiar with the matter. Reference Link
September 8, 2014
12:40 EDTABBVFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
07:15 EDTABBVIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
06:54 EDTWAGWalgreen appoints JANA's Barry Rosenstein to board of directors
Subscribe for More Information
05:50 EDTWAGStocks with implied volatility movement; DE WAG
Stocks with implied volatility movement; Deere (DE) 15, Walgreen (WAG) 30 according to iVolatility.
September 5, 2014
12:42 EDTWAGStocks with increasing options volume
Stocks with increasing options volume: VALE MCP KORS WAG GM PCLN
11:47 EDTWAGOptions with increasing implied volatility
Subscribe for More Information
10:55 EDTWAGWalgreen call activity attributed to activist investor speculation
Subscribe for More Information
10:00 EDTWAGRumor: Walgreen strength attributed to activist investor speculation
Subscribe for More Information
07:31 EDTWAGWalgreen notifies customers about label printing errors, WSJ reports
Walgreen has found that its systems were printing drug labels with random characters in the instructions during a recent system crash, making some hard to understand, and has reached out to notify thousands of customers about the issue, reported The Wall Street Journal, citing a company spokesman and an internal memo. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use